Dec 18 (Reuters) - Chinese government approval for imports of a controversial type of Syngenta AG biotech corn increases the likelihood the seed maker will pay settlements to more than 100 U.S. farmers and exporters suing for damages
CHICAGO, Dec 17 (Reuters) - A top Chinese government official said the country has approved imports of genetically modified Agrisure Viptera corn and two varieties of biotech soybeans after years of review, U.S. Agriculture Secretary Tom Vilsack said on Wednesday.
(Updates with additional comments, background starting in fourth paragraph.)
CHICAGO, Dec 17 (Reuters) - The United States and China are making progress on talks over Beijing's acceptance of new biotechnology for crops, U.S. Agriculture Secretary Tom Vilsack said on Wednesday.
BRUSSELS, Dec 16 (Reuters) - Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a programme to develop a new drug to treat bowel disease.
term prospects. Winner: Growth Funds That Like Health Care Primecap's growth funds are all fond of health care, including biotech , and they produced returns between 15% and 20%, all topping nearly all of their peers. ClearBridge Aggressive Growth SHRAX
generating free cash flows with sound balance sheets that are far removed from the headline exciting stocks in social media, biotech , internet shopping etc., currently being purchased by the investment masses ( who we believe are paying little attention
several of its development programs. While Alnylam has one of the most plentiful (albeit mostly early-stage) pipelines in biotech , and despite our FVE increase, we think its shares are fully valued at recent prices. The R&D day provided few surprises
ZURICH, Dec 15 (Reuters) - Genentech, U.S. biotech unit of Swiss drugmaker Roche holding, said on Monday it had filed a marketing application to U.S. regulators for the use of
ZURICH (Reuters) - Roche said the head of research operations at its subsidiary Genentech would retire at the end of the year, the latest in a string of executives to leave the Californian biotech unit.